Codiak Biosciences Inc
CDAK
Get informed when a big investor buys or sells
+ FollowShare Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $10.88 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.91 |
| Beta | 3.93 |
| Outstanding Shares | 25,159,757 |
Return
| Return on Equity | -75.10% |
|---|---|
| Return on Assets | -21.75% |
| Return on Invested Capital | -44.44% |
Valuation & Multiples
| P/E Ratio | -0.03 |
|---|---|
| PEG | 0.14 |
| Price to Sales | 0.06 |
| Price to Book Ratio | 0.06 |
| Enterprise Value to Revenue | 0.32 |
| Enterprise Value to EBIT | -0.2 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 5.76 |
| Debt to Equity | 1.61 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Codiak Biosciences Inc
105 employees
CEO: Douglas Williams Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unm...
Relevant Senate Committees
Controls Medicare and Medicaid reimbursement policies and tax credits for R&D, which are primary drivers of long-term commercial viability for biotechs.
Determines the exact funding levels for the FDA and NIH, which are essential for the regulatory review and foundational funding of CDAK's research.
Directly regulates the FDA and NIH. Members have advanced knowledge of drug approval pathways, clinical trial requirements, and federal research grants.
Direct oversight of intellectual property and patent laws is critical for clinical-stage companies whose valuation is almost entirely dependent on proprietary technology.